Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Broadens Scope Of Clinical Studies For Breast Cancer Therapy Lapatinib

This article was originally published in The Pink Sheet Daily

Executive Summary

The company outlined an expanded Phase III development program for Tykerb (lapatinib) during an oncology R&D update.

You may also be interested in...



GSK Tykerb Positive Trial Data Prompt Earlier Submission

Data monitoring committee halts Phase III trial of lapatinib in breast cancer after it exceeds its primary endpoint.

GSK Tykerb Positive Trial Data Prompt Earlier Submission

Data monitoring committee halts Phase III trial of lapatinib in breast cancer after it exceeds its primary endpoint.

GSK Lapatinib Breast Cancer Filing Delayed; Focus Shifts To Front-Line

Following favorable Phase II interim results, lapatinib clinical efforts will be refocused on the front-line setting, GSK says. Phase III program is ongoing. Firm had planned to submit based on Phase II studies in highly refractory disease, but results were not sufficient for filing.

Related Content

Topics

UsernamePublicRestriction

Register

PS061336

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel